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Inactivation of the Rb-mediated G1 control pathway is a common event found in many types of human
tumors. To test how the Rb pathway interacts with other pathways in tumor suppression, we characterized mice
with mutations in both the cyclin-dependent kinase (CDK) inhibitor p18Ink4c and the lipid phosphatase Pten,
which regulates cell growth. The double mutant mice develop a wider spectrum of tumors, including prostate
cancer in the anterior and dorsolateral lobes, with nearly complete penetrance and at an accelerated rate. The
remaining wild-type allele of Pten was lost at a high frequency in Pten/ cells but not in p18/ Pten/ or
p18/ Pten/ prostate tumor cells, nor in other Pten/ tumor cells, suggesting a tissue- and genetic
background-dependent haploinsufficiency of Pten in tumor suppression. p18 deletion, CDK4 overexpression, or
oncoviral inactivation of Rb family proteins caused activation of Akt/PKB that was recessive to the reduction
of PTEN activity. We suggest that p18 and Pten cooperate in tumor suppression by constraining a positive
regulatory loop between cell growth and cell cycle control pathways.
Genetic and pathological analyses of both human popula-
tions and transgenic animal models have established that tu-
morigenesis is a multistep process involving alteration of both
proto-oncogenes and tumor suppressor genes in a single indi-
vidual tumor cell. Functional collaborations between gain-of-
function mutations of activated oncogenes and between loss-
of-function mutations targeting tumor suppressor genes are
common events required for the progressive evolution of a
normal cell into a cancerous one (13). One of several well-
characterized tumor suppression pathways is the Rb pathway,
which includes three related proteins in mammalian cells, pRb,
p107, and p130, that play critical roles collaboratively in con-
trolling mammalian G1 cell cycle progression (32). Emerging
from mitosis or present in quiescent cells as hypophosphory-
lated forms, these proteins negatively regulate the activity of
E2F transcription factors to prevent S-phase entry. Extracel-
lular mitogens induce the expression of D-type cyclins and
activate cyclin D-dependent kinases CDK4 and CDK6, leading
to phosphorylation and functional inactivation of Rb proteins.
Conversely, inhibition of CDK4 and CDK6, resulting from
either lack of cyclin D synthesis or binding with an INK4
protein, retains Rb proteins in their growth-suppressive states
and prevents the G1-to-S transition. Disruption of this path-
way, consisting of INK4-cyclin D/CDK4/6-Rb-E2F, deregu-
lates G1 cell cycle progression and is a common event for the
development of most types of cancer (28). Genetic study in
targeted mice provides strong support for a critical function of
this pathway in tumor suppression. Mice develop spontaneous
tumors when they are heterozygous for Rb (14, 21), chimeric
for Rb/ (22, 33), deficient for CDK inhibitors p18Ink4c (11,
12, 20) and p16Ink4a (18, 27), or carrying an INK4-insensitive
mutation (R24C) in CDK4 (29).
A persistent puzzle from the studies of mice with germ line
mutations impairing the Rb pathway is why tumors that de-
velop in these mice exhibit a spectrum different from that
observed in human patients. While heterozygosity of the Rb
gene is causally linked with the development of retinoblastoma
(17), mice heterozygous for Rb or chimeric for Rb/ devel-
oped tumors almost exclusively in neuroendocrine organs, in-
cluding the characteristic intermediate lobe of the pituitary
and four additional endocrine organs: the thyroid, parathyroid,
adrenal glands, and pancreatic islets. Moreover, germ line mu-
tations in mice that targeted the upstream activators of Rb, the
CDK inhibitor genes, resulted in the development of neuroen-
docrine tumors with a very similar spectrum: single p18/ and
p27/ deficient mice develop slow-growing intermediate lobe
pituitary tumors (11), and the p18 p27 double mutant mice,
either three-fourths or double null, develop tumors with a
complete or high penetrance in the same endocrine cells as in
Rb mutant mice by the age of 4 months (12). The bases of the
tissue specificity of tumor development and of the species
difference caused by the germ line mutations targeting the
Rb pathway are not known. One explanation of the tissue
specificity of tumors developed in mice with reduced func-
tion of the Rb pathway is that the functional collaboration
between the Rb and other pathways controlling different
cellular processes may determine the spectrum of tumor
specificity. To test how tumor suppressor genes acting on
different pathways collaborate with each other to suppress
tumor development, we set out to characterize mice with
compound mutations in p18 and Pten.
The PTEN (phosphatase and tensin homolog deleted from
chromosome 10, also known as MMAC1 or TEP1) tumor
suppressor is located on a genomic region that frequently suf-
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fers loss of heterozygosity (LOH) in different types of ad-
vanced human cancer, including prostate cancer (4). Genetic
analysis of Pten mutant mice sustaining monoallelic or null
mutations supports a key function of PTEN in suppressing
prostate tumor development (7, 9, 25, 30, 31). The biochem-
ical mechanism underlying PTENs tumor suppression func-
tion is believed to lie in its phosphatase activity. Most mis-
sense mutations in Pten detected in primary tumors and in
established cell lines are confined to exon 5, encoding the
phosphatase domain. The main in vivo substrate of PTEN
phosphatase activity is the lipid second messenger, phospha-
tidylinositol 3,4,5-triphosphate (23), placing PTEN into a
previously defined signaling pathway in which the proto-
oncogene serine/threonine kinase Akt is a major effector of
PTEN. The cellular function of PTEN was recently linked to
cell growth control by the findings that TSC1/2, a het-
erodimeric complex consisting of TSC1 and TSC2 whose
mutations predispose individuals to hamartomas in many
tissues and inhibit mTOR-mediated protein synthesis, is a
major downstream target of AKT (3). We reasoned that
simultaneous stimulation of cell growth, resulting from a
reduction of PTEN activity, and the cell cycle, caused by the
loss of function of p18, may more effectively promote tumor
development than the alteration of either pathway alone.
We report in this paper the characterization of tumor de-
velopment in p18-Pten double mutant mice.
MATERIALS AND METHODS
Mice. The generation and genotyping of p18 and Pten mutant mice have been
described previously (8, 11). p18 and Pten mutant mice have been backcrossed
for 9 and more than 15 generations with C57BL/6 mice, respectively. Cohorts
were housed and analyzed in a common setting, and littermate controls were
used for all experiments as indicated.
Histopathology, immunological procedures, and antibodies. Tissues were
fixed and examined by two pathologists after hematoxylin-eosin staining. Immu-
nohistochemistry was performed as described previously (2). To measure prolif-
erating and mitotic cells, sections were blocked with normal goat serum in
phosphate-buffered saline and incubated with the antibody against phospho-
histone H3 (5 g ml1) followed by biotin-conjugated secondary antibody. Im-
munocomplexes were detected using the Vectastain ABC alkaline phosphatase
kit. Terminal deoxynucleotidyltransferase-mediated dUTP biotin nick end label-
ing (TUNEL) assays were carried out using an in situ ApopTag kit (Intergen)
according to the manufacturer’s protocol. Antibodies to phospho-AktSer473, cal-
citonin (Research Diagnostics), B220, CD3 (BD Pharmingen), Akt, phospho-
S6KThr389 (Cell Signaling Technology), myc (9E10), simian virus 40 large T
(Oncogene), phospho-histone H3 ser10 (Upstate Biotechnology), and actin
(Santa Cruz Biotechnology, Inc.) were purchased commercially.
Laser capture microdissection and LOH analysis. Laser capture microdissec-
tion was used to obtain pure cell populations of selected areas from paraffin-
embedded tissue sections. Ten-micrometer sections were deparaffinized and
lightly stained with hematoxylin. Using a PixCell lle laser capture microdissection
system (Arcturus, Mountain View, CA), the lesions that were clearly separated
from normal tissues were isolated from the slides. DNA was isolated from the
microdissected tissue samples as described before.
Cell culture, treatment, and transfection. LNCaP and DU145 cells were cul-
tured in RPMI 1640 medium with 10% fetal bovine serum. Cells were transfected
with FuGene. Where indicated, 20 M LY294002 or dimethyl sulfoxide solvent
was added to the cells 24 h prior to lysis.
Statistical analyses. All of the statistical analyses were performed with the
program StatsDirect 2.4.3 (StatsDirect Statistical Software). The survival rate
was calculated by the Kaplan-Meier method. Fisher’s exact test was used to test
for the difference in the probability of developing tumors between mice with
compound deletions and those with single gene deletions.
RESULTS
Accelerated tumorigenesis in p18 Pten double mutant mice.
To test the genetic interaction between p18 and Pten, we mated
p18/ homozygotes with Pten/ heterozygotes, both from a
C57BL/6 background, to generate animals heterozygous for
both genes. These mice were intercrossed to generate both
p18/ Pten/ and p18/ Pten/ animals. Genotype anal-
ysis of more than 200 offspring did not identify any p18/
Pten/ double null mice, nor were any viable p18/ Pten/
embryos identified beyond embryonic day 7.5 (data not
shown). These results indicate that deletion of p18 does not
rescue the embryonic lethality caused by Pten loss.
A cohort of 54 p18/ Pten/ and 32 p18/ Pten/ mice
was monitored for their development and survival along with
p18/ (n  46), Pten/ (n  35), and wild-type mice (n 
30) (Fig. 1a). Both p18/ Pten/ and p18/ Pten/ mice
undergo normal development overall into their adulthood, and
no significant developmental defects were detected. However,
both mice had a decreased life span compared to either
Pten/ or p18/ mice. Whereas most p18/ mice lived
beyond 500 days and the mean age at death of Pten/ mice
was 303 days, the mean ages at death of p18/ Pten/ and
p18/ Pten/ mice were 245 and 187 days, respectively,
which was significantly lower than Pten/ or p18/ alone
mice (Fig. 1a). The direct cause of earlier death of these
double mutant mice, as in the case for Pten/ mice (8), is
likely the kidney failure caused by autoimmune glomerulo-
pathy, which was accelerated by the p18 loss. Pten/ mice,
beginning at 3 months of age, developed lymphadenopathy
affecting mainly the submandibular and axillary lymph nodes.
By the age of 6 months, most lymph nodes were between 0.5
and 1.5 cm in size, and the average size was 0.96  0.45 cm
(mean  standard deviation) in diameter (Fig. 1b and c). The
development of lymphadenopathy was accelerated by p18 loss;
all p18/ Pten/ double mutant mice developed lymphadeno-
pathy at the age of 3 months. Most lymph nodes were larger
than 1.5 cm, and the average size was 2.1  0.71 cm by the age
of 6 months in these double mutant mice (Table 1; Fig. 1c).
Severe autoimmune glomerulopathy became evident as early
as 3 months of age in the p18/ Pten/ mice, which might
have contributed to the renal failure associated with the early
death of p18/ Pten/ mice. The lymphocytes from enlarged
lymph nodes and spleens from both Pten/ and p18/
Pten/ mice were polyclonal, as verified by staining of the
T-cell marker CD3 and the B-cell marker B220 with immuno-
histochemistry (IHC) and flow cytometric analysis (data not
shown).
The p18 Pten double mutant mice developed tumors at an
accelerated rate with a wider spectrum than either single mu-
tant. As a brief overview, 74% (n  19) of p18/ Pten/
double mutant mice developed pituitary tumors in both ante-
rior and intermediate lobes by the age of 10 months, whereas
none of the p18/ or Pten/ single mutant mice developed
tumors in both lobes (Fig. 2). Pheochromocytomas developed
in the adrenals of 84% of p18/ Pten/ mice, compared to
65% in Pten/ and 14% in p18/ mice, and these were more
aggressive, compressing the adrenal cortex, exhibiting more
mitotic figures, and frequently invading into the cortex and
surrounding tissues (Fig. 3). C-cell tumors developed in 63%
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(n  19) of p18/ Pten/ mice, compared with only 14%
(n  14) and 15% (n  20) of p18/ and Pten/ mice,
respectively. Moreover, half of the p18/ Pten/ mice de-
veloped thyroid tumors of both C cells and follicular cells, but
only 15% of Pten/ mice and no p18/ mice developed
thyroid tumors in both cell types (Table 1; Fig. 3). At 6 months
of age, 80% of p18/ Pten/ mice displayed high-grade pros-
tatic intraepithelial neoplasia (PIN) in both the anterior and
dorsolateral prostatic lobes, including 20% invasive tumors,
compared with only one in eight (13%) Pten/ mice and no
p18/ mice developing high-grade PIN. Late in life (12
months), all p18/ Pten/ mice, as opposed to half of the
Pten/ and none of the p18/ mice, developed high-grade
PIN (Fig. 4). Nearly every p18/ Pten/ mouse developed
multiple tumors in different organs. These results offer a
glimpse of the data that support a functional collaboration
between p18 and Pten in suppression of tumorigenesis.
p18/ Pten/ mice developed pituitary tumors in both the
anterior and intermediate lobes. Consistent with previous re-
ports (11, 12), more than half of the p18/ mice developed
pituitary intermediate lobe tumors between 6 and 16 months of
age. Thirty-five percent of Pten/ mice also developed pitu-
itary tumors between 6 and 14 months of age, a phenotype that
has not been previously reported. Unlike the characteristic
intermediate lobe tumors that developed in mice with reduced
or disrupted function of genes acting on the Rb pathway, all
the pituitary tumors that arose in Pten/ mice were located in
the anterior lobe (Fig. 2). Loss of one p18 allele did not sig-
nificantly increase the incidence of anterior lobe tumors in
Pten/ mice, but p18 nullizygosity shortened the latency of
FIG. 1. Survival and lymphadenopathy of p18 and Pten mice. (a) The graph summarizes the viability of mice with each genotype. The mean age
of survival is given in Results. (b) Mice of different genotypes of the same litter at 6 months of age. Enlarged lymph nodes are indicated. (c) Gross
appearance of lymph nodes from different mice at 6 months of age.
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anterior lobe tumors from 11.5  3 months in Pten/ mice to
7.5  2 months in p18/ Pten/ mice and increased the
incidence of anterior lobe tumors from 35% in Pten/ mice to
74% in p18/ Pten/ mice (Table 1). Although Pten/ mice
did not develop obvious pathological abnormalities in the in-
termediate lobe, the incidence of intermediate lobe tumors was
increased from 57% in p18/ mice to 84% in p18/ Pten/
(Table 1 and Fig. 2).
To confirm the functional collaboration between p18 and
Pten in suppressing pituitary tumor development in both lobes,
we carried out more detailed histological analyses of mice of
different genotypes at both an early age (3 to 6 months) (Fig.
2a) and late in life (after 6 months) (Fig. 2b). At the early age,
both p18/ single mutant and p18/ Pten/ double het-
erozygous mice developed hyperplasia in the intermediate
lobe, while nearly all Pten/ pituitaries were normal. At this
age, 25% of p18/ Pten/ mice had already developed ade-
nomas in the intermediate lobe and, notably, one out of eight
mice also developed an adenoma in the anterior lobe, a phe-
notype that was not visible in p18/, p18/ Pten/, or
Pten/ mutant mice at this age. Late in life, 5 of 20 (25%) and
2 of 20 (10%) Pten/ mice developed adenoma and adeno-
carcinoma, respectively, exclusively in the anterior lobe (Fig.
2b). Eight of 14 (57%) p18/ mice developed intermediate
lobe adenoma and adenocarcinoma. Remarkably, 14 of 19
(74%) of p18/ Pten/ mice developed adenoma and ade-
nocarcinoma in both anterior and intermediate lobes. The
tumors in the p18/ Pten/ mice were more aggressive and
severe; hemorrhaging, necrosis, and invasion into adjacent tis-
sues were evident (Fig. 2b). Immunostaining of serial pituitary
sections with antibodies to mitotic phosphorylated histone H3
revealed an increase of cell proliferation in the p18/ Pten/
pituitary and an even higher level of proliferation in p18/
Pten/ cells than either p18/ or Pten/ pituitaries (Fig.
2c), indicating that Pten, like p18, also plays a role in restrain-
ing cell proliferation.
Loss of both p18 and p27 resulted in spontaneous develop-
ment of hyperplastic tissues and/or tumors in the pituitary,
adrenals, thyroid, parathyroid, testis, and pancreas (12), a phe-
notype that is similar to human multiple endocrine neoplasia
TABLE 1. Spontaneous tumor formation and incidence in p18/, Pten/, p18/ Pten/, and p18/ Pten/ mice
Organ and/or
condition






















Normal 15 6 6 9 13 8 8 6 3
Intermediate lobe tumor 0 0 8 (57)b 0 0 0 0 2 (25) 16 (84)
Anterior lobe tumor 0 0 0 0 7 (35)c 0 9 (53)d 1 (13) 14 (74)
Both 0 0 0 0 0 0 0 1 (13) 14 (74)
Adrenal
Normal 14 6 8 3 5 4 4 3 1
Medullary hyperplasia 1 0 4 4 2 2 1 1 2
Pheochromocytoma 0 0 2 (14)e 2 (22) 13 (65)f 2 (25) 12 (71)g 4 (50) 16 (84)
Cortical adenoma 0 0 0 0 0 0 0 0 2 (11)
Thyroid
Normal 15 6 12 8 7 7 3 4 1
C-cell tumor 0 0 2 (14)h 0 3 (15)i 0 3 (18)k 3 (38) 12 (63)
Follicular cell tumor 0 0 0 1 (11) 13 (65)j 1 (13) 13 (77)l 4 (50) 16 (84)
Both 0 0 0 0 3 (15) 0 2 (12) 3 (38) 10 (53)
Other tumors
Lung 0 0 2 0 2
Breast 0 0 2 1 3
Endometrial hyperplasia 0 0 3 1 2
Harderian gland 0 1 0 0 0
Harderian gland 0 1 0 0 0
Lymphadenopathy    / 
a , at the age of 6 months the average size of the lymph node was 0.96  0.45 cm; , most lymph nodes were 1 to 2 cm; , average lymph node size was 2.1 
0.71 cm.
b P  0.0047 for p18/ versus p18/ Pten/.
c P  0.001 for Pten/ versus p18/ Pten/.
d P  0.11 for p18/ Pten/ versus p18/ Pten/.
e P  0.001 for p18/ versus p18/ Pten/; P  0.0012 for p18/ versus p18/ Pten/.
f P  0.098 for Pten/ versus p18/ Pten/; P  0.36 for Pten/ versus p18/ Pten/.
g P  0.18 for p18/ Pten/ versus p18/ Pten/.
h P  0.003 for p18/ versus p18/ Pten/.
i P  0.0014 for Pten/ versus p18/ Pten/.
j P  0.098 for Pten/ versus p18/ Pten/.
k P  0.004 for p18/ Pten/ versus p18/ Pten/.
l P  0.2 for p18/ Pten/ versus p18/ Pten/.
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(MEN) syndromes and implicates p18 and p27 as MEN genes.
One puzzling difference between the clinical manifestation of
human MEN syndromes and the phenotypes that developed in
p18/ p27/ mice is that while MEN patients develop pitu-
itary tumors in the anterior lobe, nearly all pituitary tumors
that developed in p18/ p27/ mice were from the inter-
mediate lobe. Identification of a p18 function in the anterior
lobe provides further support for a role of p18 in suppres-
sion of MEN.
Twenty to 25% of humans develop pituitary adenomas, as
revealed by autopsy, and nearly all lesions develop in the an-
terior lobe, not the intermediate lobe (10). The prevalence of
FIG. 2. Collaboration between Pten and p18 in suppression of pituitary tumors. (a) Pituitary glands (arrows) from different genotypes of mice
of the same litter were microscopically examined at 3.5 months of age either directly (top row) or after hematoxylin and eosin staining (bottom
row). Anterior lobe (A), intermediate lobe (I), neurohypophysis (N), and a tumor (T) are indicated. (b) Pituitary tumorigenesis in different
genotypes of mice late in life (after 9 months). The boxed area in the Pten/ image is magnified in the inset. The arrow indicates the area of
invasion from the anterior lobe into surrounding bone tissue. The lower right inset for p18/ Pten/ shows the area of invasion from the
intermediate lobe into the anterior lobe (arrow). The lower left inset for p18/ Pten/ shows the anterior lobe tumor invading into the
surrounding brain tissue (arrowhead). (c) Series of sections of pituitary glands from mice of different genotypes at 9 months of age were examined
for mitotic activity by immunostaining with an antibody recognizing phosphorylated histone H3. Boxed areas are magnified in the insets (anterior
lobe [lower left] and intermediate lobe [upper left]).
4568 BAI ET AL. MOL. CELL. BIOL.
FIG. 3. Collaboration between Pten and p18 in suppression of thyroid and adrenal tumors. (a) Hematoxylin and eosin staining of thyroids from
mice of different genotypes at 3 months of age. Hyperplasia (H) and tumor (T) are indicated. (b) Thyroid tumors from mice of the same litter were
examined at 9 months of age by hematoxylin and eosin staining and by immunostaining for calcitonin. Follicular cell adenoma (FA) and C-cell
carcinoma (CC) are indicated. Calcitonin-containing tumor cell invasion is indicated by an arrow. (c) Immunostaining of the thyroid from wild-type
(WT) and p18/ mice (12 months of age) and of C-cell tumors from Pten/ (12 months of age) and p18/ Pten/ (9 months of age) mice for
phospho-Akt. (d) Gross appearance of adrenal glands from Pten/ (10 months of age), p18/ Pten/ (9 months), and WT and p18/ (13 months)
mice. (e) Hematoxylin and eosin staining of adrenal glands from different genotypes. Hyperplasia (H) and pheochromocytoma (T) of the adrenal medulla
(AM) compressing the adrenal cortex (AC) are indicated. The arrow indicates the area of invasion from the medulla into the cortex. Note the intact
medulla-cortex boundary in Pten/ mice and disruption of the boundary in p18/ Pten/ mice.
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FIG. 4. p18 and Pten cooperate in prostate tumor suppression. (a) Gross appearances of age-matched wild-type (WT) and p18/ mice (12
months) are shown. Significant enlargement of the dorsolateral prostate (DLP) was seen. SV, seminal vesicle; BL, bladder. (b) Representative
hematoxylin and eosin staining of prostates from mice of different genotypes at 6 months of age. Diagnostic criteria for PIN are described in the
text. (c) Representative invasive adenocarcinoma from p18/ Pten/ prostates at 9.5 months of age. Nests of tumor cells invading into the stroma
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these tumors has long been underestimated because of their
small size and noninvasive nature. Although the mortality rate
is low, pituitary adenomas cause various symptoms, such as
inappropriate hormone secretion, headaches, and deteriora-
tion of visual acuity. These results thus also suggest the p18-
CDK4-Rb pathway as a potential target for therapeutic inter-
vention of both MEN and pituitary adenoma.
Accelerated thyroid tumorigenesis in p18/ Pten/ mice.
Thyroid tissues contain large follicles surrounded by follicular
cells and scattered C cells. Consistent with a previous report
(7), we detected follicular cell tumors in 14 out of 29 (48%)
Pten/ mice and C-cell tumors at a much lower incidence (3
out of 29) (Fig. 3a). Two out of 20 p18 null mice developed
thyroid tumors, all of which were C-cell tumors (Table 1). The
C-cell origin of these tumors was verified by immunohisto-
chemistry using an antibody to calcitonin (Fig. 3b). Most tu-
mors derived from both Pten/ and p18/ mutant mice were
small, confined to one lobe, and did not alter the gross appear-
ance of the thyroid. p18 deficiency shortened the latency and
changed the spectrum of thyroid tumor development in
Pten/ mice. Between the ages of 3 and 6 months, half (four
of eight) of the p18/ Pten/ mice had already developed
follicular cell tumors, three of which were combined with C-
cell tumors, while no C-cell tumors were found in p18/ or
Pten/ mice, and only one out of nine Pten/ mice devel-
oped a follicular cell tumor at the same age (Table 1). Late in
life (6 months), 63% of p18/ Pten/ mice had C-cell
tumors, compared with only 14% and 15% of p18/ and
Pten/ mice at the same age, respectively. Sixteen out of 19
(84%) of the p18/ Pten/ mice developed follicular cell
tumors, higher than the incidences of follicular cell tumors in
both p18/ Pten/ (77%) and Pten/ (65%) mice (Table 1).
Fifty-three percent of p18/ Pten/ thyroids that developed
C-cell tumors also developed follicular cell tumors, either in
the same lobe or the other lobe. Tumors that arose in p18/
Pten/ thyroids were large, obvious by gross analysis, and
often bilateral, indicating increased malignancy over the tu-
mors that arose in either p18/ or Pten/ thyroids at a
similar age.
Immunostaining of the thyroid tumors with an antibody to
Ser473-phosporylated Akt revealed an increased level of acti-
vated Akt that accumulated mostly at the plasma membrane in
Pten/ thyroid C cells (Fig. 3c). Deletion of p18 resulted in a
notable increase of Ser473-phosphorylated Akt in the presence
of both Pten alleles and synergistically activated Akt in Pten/
thyroid C cells, suggesting a negative regulation of Akt activa-
tion by p18.
Adrenal tumorigenesis in p18 Pten double mutant mice. Two
out of nine (22%) Pten/ mice and none of the p18/ mice
developed pheochromocytomas between 3 and 6 months, re-
spectively, while late in life, 65% of Pten/ and 14% of p18/
mice developed pheochromocytomas (Table 1 and Fig. 3d).
The tumors that occurred in either p18/ or Pten/ mice
were generally small and occasionally invasive into the cortex,
and the majority of these tumors were unilateral. On the other
hand, the adrenal glands of p18/ Pten/ mice were clearly
larger by gross examination than age-matched p18/ or
Pten/ mice (Fig. 3d). At an early age, half of the p18/
Pten/ mice displayed pheochromocytoma. By the age of 10
months, most p18/ Pten/ mice developed pathological
abnormalities in the adrenals, ranging from severe medulla
hyperplasia (11%) or pheochromocytoma (84%) to pheochro-
mocytoma combined with cortical adenoma (11%). Ten out of
16 (63%) of the p18/ Pten/ mice displayed bilateral pheo-
chromocytoma, and 2 mice simultaneously developed pheo-
chromocytoma and cortical adenoma (Table 1). The pheochro-
mocytomas that arose in p18/ Pten/ mice were more
aggressive than those that developed in p18/ or Pten/
single mutant mice; they were larger in size, compressing the
adrenal cortex, exhibited more mitotic figures, and frequently
invaded into the cortex and surrounding tissues (Fig. 3e). The
earlier onset, increased incidence, and malignancy of adrenal
tumor phenotypes in p18/ Pten/ mice indicate a func-
tional collaboration between p18 and Pten in suppression of
adrenal tumorigenesis. These results are consistent with a
model that, while both genes participate in suppression of
pheochromocytoma and cortical adenoma development in the
adrenal glands, Pten plays a more prominent role and acts at an
earlier stage than p18.
p18/ Pten/ mice developed prostate tumors in the an-
terior and dorsolateral lobes. Pten/ mice are highly prone to
the development of PIN (7, 25, 31). Close examination of old
p18/ male mice revealed an evident enlargement of their
prostate glands, approximately 80% larger than age-matched
wild-type mice (Fig. 4a). At 6 months of age, most Pten/
prostates developed low-grade PIN (the prostatic epithelium
displayed one or two layers of atypical cells), while the p18/
prostates were normal (Fig. 4b). One out of eight Pten/ mice
developed high-grade PIN, including lesions that were large,
with pleomorphic nuclei and cells filling the lumen, but the
duct outline was intact, and lesions that contained atypical cells
that filled the lumen and bulged focally into or invaded into
surrounding tissues. An evident functional collaboration be-
tween p18 and Pten in suppressing prostate tumorigenesis was
seen by the increased incidence of high-grade PIN and the
presence of invasive adenocarcinoma in the double mutant
mice, both p18/ Pten/ and p18/ Pten/, over that in
Pten/ single mutant mice (Fig. 4b, c, and d). Four out of five
(80%) p18/ Pten/ double heterozygotes displayed low-
grade PIN with two or more layers of atypical cells, and 20%
developed high-grade PIN (Fig. 4b and d). Prostate tumori-
genesis was further accelerated by the loss of both p18 alleles;
80% of p18/ Pten/ mice displayed high-grade PIN in both
the anterior and dorsolateral prostatic lobes by 6 months of
age. Twenty percent of p18/ Pten/ prostate tumors were
microinvasive, as seen by the rupture of the basal membrane of
areas are indicated. (d) The high-grade PIN and carcinoma-free curve shows that reduction of the p18 gene significantly enhanced high-grade PIN
and carcinoma susceptibility in Pten/ mice. (e) Increase of cell proliferation in p18 Pten double mutant prostatic epithelium. Eight-week-old
tumor-free prostates from mice of different genotypes were stained with antibody recognizing phosphorylated histone H3. Positive nuclei were
counted in 10 randomly chosen fields.
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FIG. 5. Loss of the remaining wild-type Pten allele is tissue-specific and is protected by p18 loss. (a) Serial sections of prostate tumors from
Pten/ and p18/ Pten/ mice were immunostained with activated Akt and PTEN. Note the strong p-Akt staining in the tumor (T) cells and
very faint (negative) p-Akt staining in the normal (N) epithelium. In Pten/ prostates, there is a mutually exclusive staining pattern between Pten
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the epithelium. At 9 months of age, all of the p18/ Pten/
and 40% of p18/ Pten/ prostates displayed high-grade
PIN lesions or carcinomas, respectively, while 20% of the
Pten/ prostates developed high-grade PIN. By 12 months of
age, all of the p18/ Pten/ mice also displayed high-grade
PIN or carcinoma, whereas half of the Pten/ prostates re-
mained free of high-grade PIN (Fig. 4b, c, and d).
To determine the cellular basis of the p18-Pten collabora-
tion, we analyzed cellular proliferation and apoptosis in the
prostates of different genotypes from 8-week-old tumor-free
mutant mice. As determined by TUNEL assays, no significant
difference in the rate of apoptosis was detected in the prostates
of different genotypes at this age (data not shown). Immuno-
staining with an antibody to mitosis-specific phosphorylated
histone H3 revealed an increase of cell proliferation in the
p18/ and Pten/ prostatic epithelium (Fig. 4e). The mitotic
index was further increased in both p18/ Pten/ and p18/
Pten/ double mutant prostatic epithelium over the p18/
cells (Fig. 4e). These results suggest that, as in the case of
pituitary tumor development, reduction of Pten activity, like
p18 loss, promoted cell proliferation.
Pten haploinsufficiency in tumor suppression is tissue spe-
cific. Development of tumors from Pten heterozygotes offered
an opportunity to address the issue of Pten haploinsufficiency
in tumor suppression. We took two approaches to this end:
IHC of PTEN and activated Akt, and LOH analysis of the
remaining Pten wild-type alleles. Pten was expressed in normal
epithelium but not in tumor cells in Pten/ prostates (Fig. 5a).
Consecutive sections of the same tumor were stained with an
antibody to Ser473-phosphorylated Akt and demonstrated a
substantially higher expression of activated Akt in the tumor
cells than in the normal epithelium (Fig. 5a). These results
suggest that the remaining wild-type Pten allele was lost in the
prostate tumor cells. As determined by IHC, PTEN protein
expression was lost in 9 out of 11 prostate tumors from Pten/
mice. In contrast, loss of PTEN protein expression was not
detected in any tumors from the pituitary (n  5), thyroid (n 
12), and adrenal glands (n  9). Activated Akt was readily
detected in all these tumors (Fig. 5a and d). These results
indicate a tissue-specific haploinsufficiency of the Pten gene in
tumor suppression.
Loss of the remaining wild-type Pten allele is protected by
p18 loss in prostate tumors. We next examined the Pten and
phospho-Akt expression patterns in p18-Pten compound mice.
Surprisingly, most p18/ Pten/ prostate tumor cells re-
tained Pten expression and yet were positive for phospho-Akt
(Fig. 5a and d). Only 2 out of 13 p18/ Pten/ and 3 out of
9 p18/ Pten/ prostate tumors lost Pten expression as de-
termined by IHC. These results revealed that loss of the wild-
type Pten allele in p18/ Pten/ mice is protected by p18 loss.
To further confirm this, we conducted laser capture microdis-
section and genomic PCR. DNA was extracted from the tumor
tissues under the microscope, and PCR-based LOH analysis
was performed. Five out of 12 prostate tumors from Pten/
mice exhibited loss of the wild-type Pten allele and retention of
the null allele, whereas none of the tumors derived from p18
Pten compound mutant mice (n  15 for p18/ Pten/ and
n  9 for p18/ Pten/) showed loss of the wild-type Pten
allele (Fig. 5b and e), further confirming that LOH is not
required for tumor development in these compound mutant
mice. In addition to prostate tumors, we also performed LOH
analysis for tumors derived from pituitary, thyroid, and adrenal
glands and found no LOH in those tumors from either Pten
alone or p18 Pten compound mutant mice (Fig. 5c and e),
suggesting that LOH occurs in a tissue-specific way in prostate
tumor development. Taken together, our results demonstrated
that loss of the wild-type Pten allele in Pten/ mice is prostate
specific and is protected by p18 loss.
p18 loss enhances Pten/-induced Akt activation in vivo,
and inactivation of the Rb pathway increases Akt activation in
vitro. To determine how p18 loss accelerates tumor develop-
ment in a Pten heterozygous background, we examined the
expression levels and distribution of activated Akt in the pros-
tates of different genotypes. Only a marginal accumulation of
activated Akt was seen in the wild-type prostatic epithelium as
well as in the p18/ prostatic epithelium despite its hyper-
plastic appearance (Fig. 6a). A clear increase of Ser473-phos-
phorylated Akt was evident in some of the PIN I and PIN II
regions of the Pten/ prostatic epithelium. As seen by the
intensity of immunostaining, there was a substantial increase of
activated Akt in most of the p18/ Pten/ cells from both
low- and high-grade PIN (Fig. 6a). To confirm the synergistic
activation of Akt by Pten reduction and p18 loss, we dissected
prostate tissues of different genotypes, prepared the total pro-
tein extract, and determined the level of both total and Ser473-
phosphorylated Akt by direct immunoblotting (Fig. 6b). The
steady-state level of total Akt was similar between wild-type
and mutant tissues of the four different genotypes. Ser473-
phosphorylated Akt was nearly undetectable in wild-type tis-
sues or in either p18/ or p18/ prostate tissues but was
easily detected in Pten/ tissues and was further increased in
p18/ Pten/ tissues. These results indicate that p18 nega-
tively regulates Akt activation in a recessive manner to PTEN
function.
Synergistic activation of Akt by Pten heterozygosity and p18
loss led us to investigate whether interference of the Rb path-
way similarly activates Akt in Pten-deficient human prostate
cells. We selected two relatively well-characterized human
and p-Akt expression in the tumor cells and normal epithelium. In p18/ Pten/ prostates, most tumor cells retained Pten expression. (b)
Presence of the wild-type Pten allele in prostate tumors of p18/ Pten/ and p18/ Pten/ mice and absence of the wild-type Pten allele in half
of the prostate tumors of Pten/ mice. DNA extracted from the microdissected samples of mice of different genotypes was amplified by PCR to
detect wild-type (wt) and mutant (mt) alleles of Pten and p18, respectively. (c) Presence of the wild-type Pten allele in other tumors of p18/
Pten/, p18/ Pten/, and Pten/ mice. DNA extracted from the microdissected samples of mice of different genotypes was amplified by PCR
to detect Pten and p18 alleles. (d) Summary of the expression pattern of Pten and p-Akt in different organ tumors from mutant mice. Pten and p-Akt
expression levels were determined by IHC, and the results are shown as the number of Pten-negative samples divided by the number of
p-Akt-positive samples, staining for the same tumor sample in consecutive sections. (e) Summary of LOH analysis of microdissected tumor samples
by PCR. The results are shown as the number of LOH divided by the number of total samples examined.
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prostatic cancer cell lines: LNCaP, which expresses the wild-
type Rb gene and is deficient for Pten, and DU145, which
expresses wild-type Pten and a mutant Rb gene. While the
steady-state level of total Akt is similar between these two cell
lines, the levels of Ser473- phosphorylated Akt are much higher
in LNCaP cells than in DU145 cells (Fig. 6c), functionally
confirming the status of Pten. The low level of activated Akt in
DU145 cells is also consistent with the observation that a
reduction of Rb pathway function is recessive to the Pten
reduction in Akt activation.
To determine whether a decrease of Rb pathway activity
would synergistically cause further Akt activation, we first
transduced these cells with retroviruses expressing CDK4.
Transduction of LNCaP cells with retroviruses expressing
CDK4 did not cause any significant change of the steady-state
level of Akt but increased the level of Ser473-phosphorylated
Akt as well as stimulated the Thr389 phosphorylation of S6K, a
major downstream target of the Akt pathway (Fig. 6c). Treat-
ment of CDK4-transduced LNCaP cells with LY294002, a se-
lective inhibitor of phosphatidyl inositol 3-kinase (PI3K), in-
hibited CDK4-induced activation of both Akt and S6K (Fig.
6d), suggesting that activation of Akt by CDK4 is dependent on
FIG. 6. Reduction or inactivation of the Rb pathway enhanced Akt activation in Pten/ prostate cells. (a) Immunostaining for p-Akt of
age-matched (9 months) prostates from mice of different genotypes. (b) Total cell lysates were prepared from the prostate tissues of mice of the
indicated genotypes. Expression levels of total and Ser473-phosphorylated Akt were determined by Western blot analysis. Expression of p-Akt was
quantified by using NIH Image (version 1.33u), and the relative level of p-Akt to total Akt is shown. (c, left) Total cell lysates were prepared from
the indicated cell lines. Expression patterns of total and Ser473-phosphorylated Akt were determined by Western blot analysis. (Right) Overex-
pression CDK4 activated Akt. Cell lysates from the indicated cell lines infected with retroviruses expressing either CDK4 or GFP were prepared,
and the steady-state levels of individual proteins were determined by Western blotting. (d) Inhibition of PI3K blocked Akt activation by CDK4.
LNcap cells infected with either CDK4 or GFP were treated with LY294002 or dimethyl sulfoxide for 24 h, and then cell lysates were collected
and analyzed by Western blotting. (e) Inactivation of Rb pathway-activated Akt and S6K. LNcap cells were transfected with pcDNA3-T121 or empty
vector for 48 h, and cell lysates were collected and analyzed by Western blotting.
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PI3K-mediated Akt phosphorylation. This finding is consistent
with the observation made in mouse prostate cells and tumors
that stimulation of Akt phosphorylation by p18 loss is recessive
to Pten reduction and that similar CDK4 expression does not
activate Akt in Pten-positive DU145 cells (Fig. 6c).
We then ectopically expressed in LNCaP and DU145 cells a
fragment of T antigen containing the N-terminal 121 amino
acids (T121) that binds to all three pocket proteins, Rb, p107,
and p130, and causes functional inactivation of the Rb path-
way. LNCaP cells transfected with a plasmid expressing T121
expressed a similar level of Akt but had substantially increased
Ser473-phosphorylated Akt as well as Thr389-phosphorylated
S6K (Fig. 6e), providing further evidence that inactivation of
the Rb pathway stimulates the PI3K-Akt pathway. Ectopically
expressed T121 in DU145 cells did not activate Akt (data not
shown).
DISCUSSION
In this paper, we provide evidence supporting a functional
collaboration between the CDK inhibitor p18Ink4c and Pten in
tumor suppression; both the rate and spectrum of tumor de-
velopment in the compound mutant mice were substantially
accelerated and expanded. Combined genetic, histological, cel-
lular, and biochemical analyses led to four major findings: (i)
that p18 and PTEN each have previously unrecognized func-
tions in tumor suppression, such as p18’s function in the pros-
tate and anterior lobe of the pituitary and PTENs function in
the pituitary, (ii) that the p18-Pten double mutant mice devel-
oped various stages of a prostate tumor phenotype in a gene
dosage-dependent manner and with a high degree of pen-
etrance, (iii) that Pten haploinsufficiency is tissue specific and is
influenced by the status of other collaborating genes, such as
p18, and (iv) that deletion of p18 or inactivation of the Rb
pathway increased activation of Akt that was recessive to the
reduction of PTEN activity.
Human prostate cancer is characterized by the long latency
between the appearance of precursor lesions (PIN) as early as
in the twenties in men and the manifestation of clinically de-
tectable carcinomas late in life (sixties or older). Historically, a
major limitation toward this goal has been the lack of suitable
animal models that faithfully recapitulate different stages of
the prostate tumor progression, in large part because of ana-
tomical differences and the differences in rate of tumor devel-
opment between the mouse and human prostate (1). The p18
Pten double mutant mice developed various stages of prostate
tumor phenotype in a gene dosage-dependent manner and
with a high degree of penetrance. Importantly, prostate tumor
phenotypes that developed in the p18 Pten double mutant mice
occurred primarily in the dorsolateral prostate, a lobe analo-
gous to the peripheral zone in the human prostate, where 80%
of human prostate cancers arise. These findings present the
p18 Pten mice, along with p27 Pten mice (7), as excellent
models for studying mechanisms underlying the functional col-
laboration between different cellular pathways in suppression
of prostate tumor development.
How widespread haploinsufficiency is among tumor suppres-
sor genes is a topic of current interest (6, 26). Not only does
this notion modify the concept that inactivating mutations in
tumor suppressor genes are recessive, but it also bears a clin-
ical implication: while both alleles of a haplosufficient tumor
suppressor gene are inactivated in tumors, a haploinsufficient
tumor suppressor gene usually retains at least one allele in
tumors and thus represents a potential target of therapeutic
intervention. The issue concerning the haploinsufficiency of
Pten has been a subject of debate. While biallelic loss of Pten
has been reported widely in human tumors, tumor-associated
LOH of Pten in mice has thus far produced a different and
more mixed pattern. The remaining wild-type Pten allele sus-
tained allelic loss in most of the radiation-induced lymphomas
derived from both Pten/ single as well as Pten/ p53/
double heterozygotes (24) and in prostate tumors that devel-
oped in Nkx3.1/ Pten/ mice (16), but it was retained in a
significant portion of prostate tumors that developed in
Pten/ TRAMP mice (19). We showed here that in Pten/
mice Pten sustained a high frequency of allelic loss in prostate
tumors but not in tumors of the pituitary, thyroid, and adrenal
glands. Furthermore, we showed that the remaining Pten allele
was lost in about half of prostate tumors that developed in
Pten/ mice but in none of the prostate tumors that devel-
oped in p18/ Pten/ or p18/ Pten/ double mutant
mice. It is surprising that even loss of one allele of p18 is
sufficient to protect Pten loss. From these results, we suggest
that the haploinsufficiency of Pten, and possibly other tumor
suppressor genes, is both tissue specific and depends on ge-
netic background.
In searching for the biochemical mechanism underlying the
p18-Pten collaboration, we found that a reduction of the Rb
pathway activity, either by the loss of p18, overexpression of
Cdk4, or inactivation of Rb family proteins, activated Akt and
its downstream target, S6K, in a manner that was genetically
recessive to the function of PTEN. The detailed biochemical
mechanisms by which the Rb pathway negatively regulates Akt
remain to be determined but, likely, the Rb pathway acts up-
stream of PI3K, since the activation of Akt by CDK4 overex-
pression can be blocked by the PI3K inhibitor (Fig. 6d). We
speculate that one or more E2F target genes, such as the
adaptor protein Grb2-associated binder 2 (5), may function
upstream of PI3K to regulate the Akt-dependent cell growth
pathway. It has long been recognized that cell cycle (cell dou-
bling) and cell growth (increase of cell mass) must be coordi-
nately regulated. Early studies from yeast cells have estab-
lished that when cell growth is blocked by nutrient deprivation
or by inactivating key biosynthetic genes, the cell cycle can no
longer proceed (15), indicating a control of cell cycle, or G1-
to-S transition, by the growth status. Our finding that a reduc-
tion of PTEN resulted in an increase of cell proliferation sup-
ports this notion (Fig. 2c and 4e). The finding that a disruption
of the Rb pathway stimulates Akt-mediated cell growth sug-
gests a cross talk between the cell growth and cell cycle path-
ways. We suggest that stimulation of the cell growth pathway
by events controlling the G1-to-S transition serves to ensure
sustained growth through the remainder of the cell cycle. As
such, a simultaneous stimulation of both pathways, such as
created here by the mutation in one negative regulator from
each pathway or mutations targeting both pathways, as ob-
served in human cancers, would prove more advantageous, if
not necessary, for cell proliferation and tumor development.
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